Table 5.
Frequency of outcome measures categorized according to relevance to transmission modelling, frequency of outcome variables, specimens collected and whether raw data were provided
| Characteristic | N | % | |
|---|---|---|---|
| Outcome measures | |||
| Observational | 90 | ||
| Prevalence | 69 | 69.70 | 1, 2, 4, 5, 7, 8, 11, 13–21, 23, 25, 27, 31–38, 43, 44, 46–48, 52, 53, 56, 58, 59, 61, 63, 65, 67, 69, 70, 73 |
| Seroprevalence | 39 | 39.39 | 3, 6, 9, 10, 12–15, 18–21, 24, 26, 29, 30, 32, 36, 38–46, 51, 53, 63, 65–73 |
| Immunity | 5 | 5.05 | 22, 36, 61, 63, 73 |
| Transmission | 5 | 5.05 | 22, 35, 61, 63, 73 |
| Duration | 3 | 3.03 | 35, 52, 61 |
| Clinical signs reported | 2 | 2.02 | 18, 22 |
| Experimental | 9 | ||
| Immunity | 5 | 5.05 | 49, 50, 55, 62, 74 |
| Transmission | 2 | 2.02 | 57, 55 |
| Duration | 7 | 7.07 | 28, 49, 50, 54, 55, 57, 64 |
| Clinical signs reported | 6 | 6.06 | 28, 49, 50, 55, 57, 64 |
| Outcome variables | 99 | ||
| Antibodies—quantified | 29 | 29.29 | 3, 6, 12, 13, 15, 18–22, 24, 29, 36, 42, 45, 46, 49, 50, 53–55, 57, 61–64, 66, 73, 74 |
| Antibodies—dichotomous | 31 | 31.31 | 3, 6, 9, 10, 14, 15, 20, 21, 24, 26, 28, 30, 32, 35, 36, 38–41, 43, 44, 50, 51, 65, 67–73 |
| Antigen—quantified | 17 | 17.18 | 17–19, 25, 27, 28, 36, 48, 49, 53–55, 57, 61, 62, 64, 73 |
| Antigen—dichotomous | 67 | 67.68 | 1, 2, 4, 5, 7, 8, 11, 13–17, 20–23, 27, 31–38, 40, 43, 44, 46, 47, 52, 53, 56, 58, 59, 61, 63, 65, 67, 69, 70, 73 |
| Infectious virus—all measures | 14 | 14.14 | 18, 25, 28, 35, 43, 48–50, 54, 55, 57, 61, 62, 64 |
| Specimen | |||
| Serum/blood | 50 | 50.51 | 3, 6, 9, 10, 12–15, 18–22, 24, 26, 28–30, 32, 35, 36, 38–47, 49, 50, 51, 53–55, 57, 61–74 |
| Nasal swab | 36 | 36.36 | 13, 14, 17–22, 25, 27, 28, 31, 32, 35–38, 40, 43, 44, 46, 48, 49, 52, 53–55, 57, 60, 61, 63–65, 67, 69, 70, 73 |
| Faeces | 13 | 13.13 | 1, 2, 4, 5, 7, 15, 16, 27, 28, 32, 34, 58, 59 |
| Rectal swabs | 23 | 23.23 | 7, 8, 13, 14, 18, 21–23, 27, 33, 34, 36, 47, 49, 50, 52–54, 56, 59, 63, 64, 73 |
| Urine | 3 | 3.03 | 18, 28, 63 |
| Milk | 4 | 4.04 | 18, 21, 52, 63 |
| Oropharyngeal | 11 | 11.11 | 22, 27, 28, 33, 47, 50, 53, 54, 56, 59, 70 |
| Other | 19 | 19.19 | 4, 17, 18, 22, 27, 28, 37, 43, 47, 49, 50, 52, 54, 55, 57, 59, 62, 64, 74 |
| Raw data provided | 20 | 20.20 | 3, 12–14, 18, 19, 21, 22, 28, 32, 41, 42, 46, 49, 50, 53–55, 65, 73 |
Each OIE MERS‐CoV animal event entered in EMPRES‐i was treated as a separate record in the review, but were included under one bibliographic entry, per FAO citation protocol.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.